AnPac Bio-Medical Science Co EBIT

AnPac Bio-Medical Science Co (ANPC) currently reports a EBIT of $-100M as of December 2022. That compares with $-110M in the prior-year period — up 6.5% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore AnPac Bio-Medical Science Co's EBIT history and peer comparisons.

AnPac Bio-Medical Science Co's EBIT increased from $-110M to $-100M — a 6.5% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AnPac Bio-Medical Science Co's EBIT of $-100M is lower than the Healthcare sector average of $22B. That is roughly 100.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

AnPac Bio-Medical Science Co reported $-100M in EBIT as of December 2022. That compares with $-110M in the prior-year period — up 6.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-100M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for AnPac Bio-Medical Science Co, and consider following ANPC for alerts when major investors trade the stock.